OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate‐to‐severe atopic dermatitis in adults: A multicentre real‐world study
Elena Pezzolo, Donatella Schena, Alessio Gambardella, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1
Closed Access | Times Cited: 22
Elena Pezzolo, Donatella Schena, Alessio Gambardella, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1
Closed Access | Times Cited: 22
Showing 22 citing articles:
Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real‐world comparative study
Tiago Torres, Jensen Yeung, Vimal H. Prajapati, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Open Access | Times Cited: 2
Tiago Torres, Jensen Yeung, Vimal H. Prajapati, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Open Access | Times Cited: 2
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, et al.
American Journal of Clinical Dermatology (2025)
Closed Access | Times Cited: 1
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, et al.
American Journal of Clinical Dermatology (2025)
Closed Access | Times Cited: 1
Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study
Teppei Hagino, Marina Onda, Hidehisa Saeki, et al.
Dermatitis (2024)
Closed Access | Times Cited: 8
Teppei Hagino, Marina Onda, Hidehisa Saeki, et al.
Dermatitis (2024)
Closed Access | Times Cited: 8
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series
Niccolò Gori, Elena Ippoliti, Silvia Ferrucci, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 10
Closed Access | Times Cited: 6
Niccolò Gori, Elena Ippoliti, Silvia Ferrucci, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 10
Closed Access | Times Cited: 6
Atopic Dermatitis in the Elderly Population
Martina Maurelli, Andrea Chiricozzi, Ketty Peris, et al.
Acta Dermato Venereologica (2023) Vol. 103, pp. adv13363-adv13363
Open Access | Times Cited: 14
Martina Maurelli, Andrea Chiricozzi, Ketty Peris, et al.
Acta Dermato Venereologica (2023) Vol. 103, pp. adv13363-adv13363
Open Access | Times Cited: 14
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis
Elena Pezzolo, Michela Ortoncelli, Silvia Ferrucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 553-553
Open Access | Times Cited: 5
Elena Pezzolo, Michela Ortoncelli, Silvia Ferrucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 553-553
Open Access | Times Cited: 5
Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study
Ersilia Tolino, Luca Ambrosio, Nicoletta Bernardini, et al.
Dermatology and Therapy (2025)
Open Access
Ersilia Tolino, Luca Ambrosio, Nicoletta Bernardini, et al.
Dermatology and Therapy (2025)
Open Access
Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Annals of Dermatology (2025) Vol. 37
Open Access
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Annals of Dermatology (2025) Vol. 37
Open Access
Higher Baseline Lactate Dehydrogenase and History of Allergic Rhinitis as Predictive Factors of Conjunctivitis in Atopic Dermatitis Patients Treated with Tralokinumab
Y Takahashi, Teppei Hagino, Hidehisa Saeki, et al.
Dermatitis (2025)
Closed Access
Y Takahashi, Teppei Hagino, Hidehisa Saeki, et al.
Dermatitis (2025)
Closed Access
Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study
Laura Marina Calabrese, Élisa Cinotti, Martina D’Onghia, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv42275-adv42275
Open Access
Laura Marina Calabrese, Élisa Cinotti, Martina D’Onghia, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv42275-adv42275
Open Access
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
Fabrizio Martora, Cataldo Patruno, Silvia D’Ascenzo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Fabrizio Martora, Cataldo Patruno, Silvia D’Ascenzo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
Yan Zhao, Jing Li, Bin Yang, et al.
BioDrugs (2024) Vol. 38, Iss. 5, pp. 681-689
Closed Access | Times Cited: 3
Yan Zhao, Jing Li, Bin Yang, et al.
BioDrugs (2024) Vol. 38, Iss. 5, pp. 681-689
Closed Access | Times Cited: 3
Innovations and Emerging Therapies in Atopic Dermatitis Part 1
Robyn Okereke, Eric L. Simpson
Current Treatment Options in Allergy (2025) Vol. 12, Iss. 1
Closed Access
Robyn Okereke, Eric L. Simpson
Current Treatment Options in Allergy (2025) Vol. 12, Iss. 1
Closed Access
Interleukin antagonists for atopic dermatitis: a new era of therapy
Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 549-559
Closed Access | Times Cited: 2
Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 549-559
Closed Access | Times Cited: 2
Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience
Silvia Ferrucci, Francesca Barei, Simona Tavecchio, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 5
Silvia Ferrucci, Francesca Barei, Simona Tavecchio, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 5
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study
Andrea Chiricozzi, Silvia Ferrucci, Lucia Di Nardo, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1307-1315
Closed Access | Times Cited: 5
Andrea Chiricozzi, Silvia Ferrucci, Lucia Di Nardo, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1307-1315
Closed Access | Times Cited: 5
Nonsteroidal Approaches for Atopic Dermatitis: A Clinical Update
Peter Ch’en, Peter Lio
Dermatitis (2024)
Closed Access | Times Cited: 1
Peter Ch’en, Peter Lio
Dermatitis (2024)
Closed Access | Times Cited: 1
Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
Laure Migayron, Sylvie Bordes, B. Closs, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Laure Migayron, Sylvie Bordes, B. Closs, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Real‐life case‐series experience with tralokinumab in patients with severe atopic dermatitis
Francesca Caroppo, Anna Belloni Fortina
JEADV Clinical Practice (2023) Vol. 3, Iss. 1, pp. 296-300
Open Access | Times Cited: 3
Francesca Caroppo, Anna Belloni Fortina
JEADV Clinical Practice (2023) Vol. 3, Iss. 1, pp. 296-300
Open Access | Times Cited: 3
A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults
Elena Pezzolo, Andrea Sechi, Jacopo Tartaglia, et al.
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 3, pp. 255-266
Closed Access | Times Cited: 2
Elena Pezzolo, Andrea Sechi, Jacopo Tartaglia, et al.
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 3, pp. 255-266
Closed Access | Times Cited: 2
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Coco Dekkers, Nicolaas P. A. Zuithoff, Daphne S. Bakker, et al.
Allergy (2024)
Closed Access
Coco Dekkers, Nicolaas P. A. Zuithoff, Daphne S. Bakker, et al.
Allergy (2024)
Closed Access
Erythrodermic atropic dermatitis responding to tralokinumab after dupilumab failure
Aida Lara-Moya, Vicente Exposito-Serrano, Patricia Garbayo‐Salmons, et al.
Indian Journal of Dermatology Venereology and Leprology (2024), pp. 1-3
Open Access
Aida Lara-Moya, Vicente Exposito-Serrano, Patricia Garbayo‐Salmons, et al.
Indian Journal of Dermatology Venereology and Leprology (2024), pp. 1-3
Open Access
